Partner Headlines - ALKS

  1. Benzinga's M&A Chatter for Tuesday June 16, 2015

    Benzinga
  2. US Stock Futures Decline Ahead Of Housing Starts Report

    Benzinga
  3. Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming ...

    Benzinga
  4. Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil ...

    Benzinga
  5. US Stock Futures Edge Lower; GDP Report In Focus

    Benzinga
  6. Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting ...

    Benzinga
  7. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  8. Benzinga's Top Initiations

    Benzinga
  9. Barclays Initiates Alkermes With Overweight

    Benzinga
  10. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  11. Stocks Mostly Higher: Time Warner Clears Buy Point

    IBD
  12. Why Citigroup Placed An $85 Price Target On Shares Of Alkermes

    Benzinga
  13. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  14. Alkermes pops to 15-year high

    IBD
  15. Alkermes Hits High On Schizophrenia Drug Results

    IBD
  16. Morning Market Gainers

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. Benzinga's Volume Movers

    Benzinga
  19. 3 Biotech ETFs Rally On Merger News

    Benzinga
  20. Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

    Benzinga
  21. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  22. Alkermes Announces Completion Of Patient Enrollment In Phase ...

    Benzinga
  23. US Stock Futures Rise Ahead Of Economic Data

    Benzinga
  24. Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For ...

    Benzinga
  25. Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest ...

    Benzinga
  26. Alkermes' drug passes trial

    IBD
  27. Market Wrap For April 8: Markets Bounce Higher As Earnings Season ...

    Benzinga
  28. Stocks Rise, Led By Tech Stocks, But Volume Fades

    IBD
  29. Mid-Afternoon Market Update: Markets Recover Slightly as Coal ...

    Benzinga
  30. Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On ...

    Benzinga
  31. Alkermes' Schizophrenia Drug Passes Trial; Filing In Q3

    IBD
  32. Benzinga's Volume Movers

    Benzinga
  33. Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit ...

    Benzinga
  34. Morning Market Movers

    Benzinga
  35. Alkermes Announces Positive Topline Results From Pivotal Phase ...

    Benzinga
  36. Benzinga's Top Initiations

    Benzinga
  37. Nasdaq Back Above Water; Green Plains Jumps

    IBD
  38. LifeLock, YY Among 5 Stocks With Top Fundamentals

    IBD
  39. Stocks Fall In Higher Volume; Yandex, Twitter Drop

    IBD
  40. Stocks Weaken After Fed Minutes; Thor Rallies

    IBD
  41. Stocks End Short Week With Big Losses

    IBD
  42. Alkermes Announces Advances in Late-Stage CNS Pipeline

    Benzinga
  43. Alkermes Receives Notice of Allowance of US Patent for Novel ...

    Benzinga
  44. Ireland Home To Several Fast Growing Health Care Names

    IBD
  45. Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 ...

    Benzinga
  46. UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

    Benzinga
  47. Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development ...

    Benzinga
  48. Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

    Benzinga
  49. Acceleron Pharma IPO Pops; Fate Therapeutics On Deck

    IBD
  50. Google, LKQ, Tesla: Stocks A Marsico Manager Likes

    IBD
  51. Stocks End Mixed In Light Trade; Green Mountain Spurts Ahead

    IBD
  52. Stocks Down Modestly; Alkermes Ramps Up

    IBD
  53. Alkermes

    IBD
  54. Stocks Up, Google At High; Dow Takes Out 14,000

    IBD
  55. Regeneron, Other Biomed Stocks Rebound On New Drugs

    IBD
  56. Alkermes

    IBD
  57. Stocks Slip As Fed Stands Pat; SodaStream Trims Gain

    IBD
  58. Alkermes Trades Tightly, Holds In Buying Range

    IBD
  59. UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking ...

    Benzinga
  60. Celgene Leads 6 Medical Stocks With Bolting RS Lines

    IBD
  61. Top 4 Stocks In The Drug Delivery Industry With The Highest EPS ...

    Benzinga
  62. Stocks Hold Modest Gains; MI Homes Hits Multiyear High

    IBD
  63. Alkermes In Buy Area After Breakout In Strong Volume

    IBD
  64. Stocks Pare Early Losses, End With Modest Declines

    IBD
  65. Alkermes Announces Notice of Allowance of USPTO Application for ...

    Benzinga
  66. Alkermes Announces Positive Results from Phase 1 Study of ALKS ...

    Benzinga
  67. Biotech Alkermes Sketches Imperfect Cup With Handle

    IBD
  68. Alkermes' Acquisition Proves To Be Game-Changer

    IBD
  69. Alkermes' Corporate Presentation to be Webcast at Two Upcoming ...

    Benzinga
  70. Dow Leads Market Higher As Volume Swells

    IBD
  71. Stocks Add To Gains; DaVita HealthCare Jumps

    IBD
  72. Alkermes Flies As Q2 Results, Guidance Beat Estimates

    IBD
  73. Alkermes' Breakout Falls Victim To Market Correction

    IBD
  74. Stocks Tumble On Disappointing Earnings Reports

    IBD
  75. Why Cisco, Google And Apple All Became Big Winners

    IBD
  76. Biotech Alkermes Attracting Flocks Of Top-Rated Funds

    IBD
  77. Biogen, Cubist and Alexion Not The Only Biomed Leaders

    IBD
  78. Alkermes In Buying Range Above Cup-Base Entry

    IBD
  79. Alkermes Writes New Prescription For Growth

    IBD
  80. Lennar, Other Homebuilders Crush Profit Estimates

    IBD
  81. Health Care Sector Wrap

    FoxBusiness
  82. UPDATE: J.P. Morgan Lowers Alkermes' PT

    Benzinga
  83. UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for ...

    Benzinga
  84. Elan

    IBD
  85. Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary ...

    Benzinga
  86. Alkermes Announces a Secondary Offering of 13,900,000 Ordinary ...

    Benzinga
  87. Market Roundup

    Benzinga
  88. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  89. Alkermes Files Resale Shelf Registration in Connection with Elan ...

    Benzinga
  90. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  91. Alkermes Inc. (ALKS) Director and CEO, Alkermes plc Richard F ...

    GuruFocus
  92. Alkermes Inc. (ALKS) SVP & CFO, Alkermes plc James M Frates sells ...

    GuruFocus
  93. Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon ...

    Benzinga
  94. Benzinga's M&A Chatter for Monday January 30, 2012

    Benzinga
  95. Benzinga's Top Pre-Market Gainers

    Benzinga
  96. UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

    Benzinga
  97. Alkermes Inc. (ALKS) SVP, COO & CRO, Alkermes, Inc. Gordon G ...

    GuruFocus
  98. Benzinga's Volume Gainers

    Benzinga
  99. CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous ...

    Benzinga
  100. Feuerstein: Alkermes CEO says Bydureon Drug will be Approved ...

    Benzinga
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!